IPSEF News and Press, Ipsen From 11/07/25

Interim data from the IQIRVO ® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in improvement of fatigue and pruritus symptoms, with a well-characterized safety profile over mor...

2025-10-24 10:56:43 ET Well, I am here again with my analysis of Gilead Sciences ( GILD ). Since my last article, "Gilead Sciences: HIV Leadership Outshines Decline in COVID-19 Drug Sales," was published on 9/2, Gilead shares have risen 8.8%, outperforming the S&P 500 ( SP...

2025-10-22 11:03:48 ET Ipsen S.A. (IPSEY) Q3 2025 Earnings Call October 22, 2025 7:00 AM EDT Company Participants David Loew - MD, CEO & Director Aymeric Le Chatelier - Executive VP & CFO Christelle Huguet - Executive VP and Head of R&D ... Re...

2025-10-22 03:09:52 ET More on Ipsen S.A. Ipsen S.A. 2025 Q2 - Results - Earnings Call Presentation Ipsen S.A. (IPSEY) Q2 2025 Earnings Call Transcript Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors Historical earnings data ...

Year-to-date total sales growth of 12.1% at CER 1 , or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 financial guidance based on slower than anticipated erosio...

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressiv...

IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action, optimized for safety and efficacy Data showed a rapid onset of action, peak effect superior to placebo, and a substanti...

Bylvay ® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in Japan, offering a non-surgical treatment option for infants, young children and adults PFIC is a rar...

2025-07-31 13:24:58 ET More on Ipsen S.A. Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors Madrigal, Ipsen, SpringWorks get EU backing for their drugs Historical earnings data for Ipsen S.A. Dividend scorecard for Ipsen S.A. ...

H1 total sales growth of 11.4% at CER 1 , or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in Oncology H1 core operating income of €656m, growing by 21.9% as reported, with a core operating margin of 36.0% of tota...